---
title: Alzheimerâ€™s Disease Infusions
---
# Video Links
- [Kinsunla vs. Lequembi](https://www.youtube.com/watch?v=Imif-u-YrJY&t=1s)

# CHAT STUFF

# ğŸ° Alzheimerâ€™s Disease Infusions

This page covers **anti-amyloid infusion therapies** used in Alzheimerâ€™s disease (AD), with a focus on *clinical monitoring, safety, and documentation*.

<div class="callout">
ğŸ’— **Goal:** Help trainees understand how these therapies are used in practice and what must be checked at every visit.
</div>

---

## ğŸ§  What are AD infusions?
AD infusions are **IV anti-amyloid monoclonal antibodies** intended to reduce amyloid plaque burden in the brain.

They are:
- Used in **early AD or MCI due to AD**
- Administered on a **regular infusion schedule**
- Closely monitored due to potential adverse effects

---

## ğŸ’‰ Common Therapies
Examples you may see include:
- Lecanemab
- Aducanumab

<div class="pearl">
ğŸ¾ Focus on **monitoring and safety**, not memorizing drug trials.
</div>

---

## ğŸ“‹ What to Check Every Visit
- Current **infusion number**
- Last infusion date
- Any missed or delayed doses
- Recent **MRI results**
- New neurologic symptoms
- Anticoagulant or antiplatelet use

---

## âš ï¸ ARIA (Amyloid-Related Imaging Abnormalities)

### ARIA-E (Edema)
- Cerebral edema
- May be asymptomatic or symptomatic

### ARIA-H (Hemorrhage)
- Microhemorrhages or superficial siderosis
- Increased risk with anticoagulation

<div class="callout">
ğŸ’— **Always ask about:** headaches, confusion, dizziness, visual changes, nausea, gait changes, or focal neurologic symptoms.
</div>

---

## ğŸ§  MRI Monitoring
- MRIs are performed at **scheduled intervals**
- Imaging determines whether infusions continue, pause, or stop
- MRI findings may guide dose or schedule changes

---

## ğŸ“ Documentation Tips
Include:
- Infusion number and tolerance
- MRI date and impression
- Presence or absence of ARIA symptoms
- Any ED visits or hospitalizations
- Counseling provided

---

## ğŸ§© Assessment & Plan Language
Example:
> Today we plan to continue AD infusion therapy pending MRI review and absence of ARIA symptoms.

Include follow-up timing and safety instructions.

---

## ğŸ‘¥ Patient & Caregiver Counseling
Key points:
- Not a cure
- Intended to slow disease progression
- Safety monitoring is essential
- New neurologic symptoms should prompt immediate contact

---

## ğŸ° Key Takeaways
<div class="callout">
ğŸ’— Safety and monitoring matter more than speed.
</div>

- Know the infusion number
- Ask ARIA questions every visit
- Document MRI status
- Involve caregivers

<div class="pearl">
ğŸ¾ When unsure, escalate questionsâ€”infusion safety comes first.
</div>
